两种粪便免疫化学检测血红蛋白系统的比较效果试验:在基于人群的结直肠癌筛查项目单轮次中评估检测性能与依从性
在意大利翁布里亚地区基于人群的结直肠癌筛查项目中开展随机对照试验(ISRCTN20086618),将48888名受邀者按1:1随机分配至HM-JACKarc或OC-Sensor粪便免疫化学检测系统。结果显示,首轮受邀者两系统筛查参与率相同,后续轮次OC-Sensor高于HM-JACKarc;首轮筛查者两系统阳性率、进展期肿瘤阳性预测值和检出率相似,后续轮次OC-Sensor阳性率高于HM-JACKarc,但进展期肿瘤阳性预测值和检出率差异无统计学意义。作者认为两系统在筛查环境中的可接受性和诊断性能相似。
要点
- 首轮受邀者两系统筛查参与率相同,后续轮次OC-Sensor高于HM-JACKarc(RR:1.03;95%CI 1.02至1.04)。
- 首轮筛查者阳性率OC-Sensor 6.5%与HM-JACKarc 6.2%相似,进展期肿瘤阳性预测值和检出率也相似。
- 后续轮次筛查者阳性率OC-Sensor 5.6%高于HM-JACKarc 4.4%(RR:1.25,95%CI 1.12至1.40),但进展期肿瘤阳性预测值和检出率差异无统计学意义。
核心结论
- 作者认为HM-JACKarc与OC-Sensor系统在筛查环境中的可接受性和诊断性能相似。
研究设计与样本
- 在意大利翁布里亚地区基于人群的结直肠癌筛查项目内开展的随机对照试验(ISRCTN20086618)。
- 符合邀请条件的受试者按1:1随机分配至HM-JACKarc或OC-Sensor粪便免疫化学检测系统进行筛查,受邀者共48888名。
主要发现
- 首轮受邀者两系统筛查参与率相同;后续轮次受邀者OC-Sensor参与率高于HM-JACKarc(RR:1.03;95%CI 1.02至1.04)。
- 首次粪便免疫化学检测筛查者中,阳性率OC-Sensor 6.5%与HM-JACKarc 6.2%相似;进展期肿瘤阳性预测值OC-Sensor 25.9%与HM-JACKarc 25.6%相似;检出率OC-Sensor 1.40%与HM-JACKarc 1.42%相似。
- 既往轮次已筛查者中,阳性率OC-Sensor 5.6%高于HM-JACKarc 4.4%(RR:1.25,95%CI 1.12至1.40)。
- 既往轮次已筛查者中,进展期肿瘤阳性预测值OC-Sensor 20.3%与HM-JACKarc 22.6%、检出率OC-Sensor 0.96%与HM-JACKarc 0.83%的差异无统计学意义。
- 检出1例进展期肿瘤需内镜检查数:首次筛查OC-Sensor 3.9(95%CI 5.8至2.9)、HM-JACKarc 3.9(95%CI 5.5至2.9);后续筛查OC-Sensor 4.9(95%CI 5.8至4.2)、HM-JACKarc 4.4(95%CI 5.3至3.7)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To compare acceptability and diagnostic accuracy of a recently available faecal immunochemical test (FIT) system (HM-JACKarc) with the FIT routinely used in an established screening programme (OC-Sensor). DESIGN: Randomised controlled trial (ISRCTN20086618) within a population-based colorectal cancer (CRC) screening programme. Subjects eligible for invitation in the Umbria Region (Italy) programme were randomised (ratio 1:1) to be screened using one of the FIT systems. RESULTS: Screening uptake among the 48 888 invitees was the same for both systems among subjects invited in the first round and higher with OC-Sensor than with HM-JACKarc (relative risk (RR): 1.03; 95% CI 1.02 to 1.04) among those invited in subsequent rounds. Positivity rate (PR) was similar with OC-Sensor (6.5%) as with HM-JACKarc (6.2%) among subjects performing their first FIT screening and higher with OC-Sensor (5.6%, RR: 1.25, 95% CI 1.12 to 1.40) than with HM-JACKarc (4.4%) among those screened in previous rounds. Positive predictive value (PPV) (OC-Sensor: 25.9%, HM-JACKarc: 25.6%) and detection rate (DR) (OC-Sensor: 1.40%; HM-JACKarc: 1.42%) for advanced neoplasia (AN: CRC + advanced adenoma) were similar among subjects performing their first FIT screening. The differences in the AN PPV (OC-Sensor: 20.3%, HM-JACKarc: 22.6%) and DR (OC-Sensor: 0.96%, HM-JACKarc: 0.83%) among those screened in previous rounds were not statistically significant. The number needed to scope to detect one AN was 3.9 (95% CI 5.8 to 2.9) and 3.9 (95% CI 5.5 to 2.9) at first and 4.9 (95% CI 5.8 to 4.2) and 4.4 (95% CI 5.3 to 3.7) at subsequent screening, with OC-Sensor and HM-JACKarc, respectively. CONCLUSIONS: Our results suggest that acceptability and diagnostic performance of HM-JACKarc and of OC-Sensor systems are similar in a screening setting. TRIAL REGISTRATION NUMBER: ISRCTN20086618; Results.
引用
- Passamonti B, Malaspina M, Fraser CG, et al. A comparative effectiveness trial of two faecal immunochemical tests for haemoglobin (FIT). Assessment of test performance and adherence in a single round of a population-based screening programme for colorectal cancer. Gut. 2016. PMID: 27974550. doi:10.1136/gutjnl-2016-312716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。